Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J-Y Reginster

Showing results (31-40 of 394) with videos related to

Pageof 40
Sort By:
Revue Medicale De Liege|May 8, 2001
[Pharmacy clinics. How I treat...Osteoarthritis. 2nd part: new therapeutic perspectives]J Y Reginster, Y Henrotin
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 21, 2007
Efficacy and tolerability of calcitonin in the prevention and treatment of osteoporosisV Halkin, J Y Reginster
Clinical and Experimental Rheumatology|April 1, 1985
Side effects of synthetic salmon calcitonin given by intranasal spray compared with intramuscular injectionJ Y Reginster, P Franchimont
Revue Medicale De Liege|January 14, 2005
[Treatment of postmenopausal osteoporosis in 2004]J Y Reginster, J P Devogelaer
Bone|November 1, 1995
Efficacy and safety of drugs for Paget's disease of boneJ Y Reginster, M P Lecart
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|May 6, 2003
Design and methodology of the phase 3 trials for the clinical development of strontium ranelate in the treatment of women with postmenopausal osteoporosisP J Meunier, J Y Reginster
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|May 6, 2003
Strontium ranelate phase 2 dose-ranging studies: PREVOS and STRATOS studiesJ Y Reginster, P J Meunier
Drugs in R&D|November 24, 1999
Promising new agents in osteoporosisJ Y Reginster, Y Henrotin, C Gosset
Bone|March 8, 2006
Adherence, patient preference and dosing frequency: understanding the relationshipJ Y Reginster, V Rabenda, A Neuprez
Revue Medicale De Liege|May 10, 2006
[Glucosamine as a pain-modifying drug in osteorthritis. What's new in 2006]J Y Reginster, F Richy, O Bruyere
Pageof 40

Showing results (31-40 of 394) with videos related to

Sort By:
Pageof 40
Revue Medicale De Liege|May 8, 2001
[Pharmacy clinics. How I treat...Osteoarthritis. 2nd part: new therapeutic perspectives]J Y Reginster, Y Henrotin
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 21, 2007
Efficacy and tolerability of calcitonin in the prevention and treatment of osteoporosisV Halkin, J Y Reginster
Clinical and Experimental Rheumatology|April 1, 1985
Side effects of synthetic salmon calcitonin given by intranasal spray compared with intramuscular injectionJ Y Reginster, P Franchimont
Revue Medicale De Liege|January 14, 2005
[Treatment of postmenopausal osteoporosis in 2004]J Y Reginster, J P Devogelaer
Bone|November 1, 1995
Efficacy and safety of drugs for Paget's disease of boneJ Y Reginster, M P Lecart
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|May 6, 2003
Design and methodology of the phase 3 trials for the clinical development of strontium ranelate in the treatment of women with postmenopausal osteoporosisP J Meunier, J Y Reginster
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|May 6, 2003
Strontium ranelate phase 2 dose-ranging studies: PREVOS and STRATOS studiesJ Y Reginster, P J Meunier
Drugs in R&D|November 24, 1999
Promising new agents in osteoporosisJ Y Reginster, Y Henrotin, C Gosset
Bone|March 8, 2006
Adherence, patient preference and dosing frequency: understanding the relationshipJ Y Reginster, V Rabenda, A Neuprez
Revue Medicale De Liege|May 10, 2006
[Glucosamine as a pain-modifying drug in osteorthritis. What's new in 2006]J Y Reginster, F Richy, O Bruyere
Pageof 40